Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy

Little is known about the optimal sequencing of targeted therapy and immunotherapy in the treatment of patients with BRAF(V600)-mutated metastatic melanoma. BRAF/MEK inhibition often has the benefit of rapid disease regression; however, resistance is frequently seen with long-term use. Treatment wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Myrdal, Caitlyn N., Sundararajan, Srinath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334770/
https://www.ncbi.nlm.nih.gov/pubmed/32670650
http://dx.doi.org/10.1155/2020/4392562

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334770/
https://www.ncbi.nlm.nih.gov/pubmed/32670650
http://dx.doi.org/10.1155/2020/4392562

Ejemplares similares